Bill > HB732

This bill establishes new requirements for medical care providers when prescribing psychotropic drugs to minors under Medicaid, focusing on informed consent and patient safety. The bill defines psychotropic drugs broadly to include stimulants (like ADHD medications), antidepressants, antipsychotics, and other behavioral drugs. Medical care providers must now provide and physically review FDA medication guides with parents or legal guardians before issuing a prescription, explaining the FDA-identified risks, pediatric-specific warnings, potential side effects, and adverse drug reactions. Additionally, providers must obtain written informed consent from the parent or guardian, confirming they have received and understood the medication guide's contents. Providers who fail to comply with these requirements may face penalties, including suspension of Medicaid reimbursements and potential reporting to the board of medicine. The legislation aims to enhance transparency, ensure parents are fully informed about the risks of psychotropic medications for children, and improve accountability in prescribing practices. The bill is set to take effect on April 1, 2026, giving healthcare providers time to adapt to the new requirements.

Health and Social Services

https://gc.nh.gov/bill_status/legacy/bs2016/bill_status.aspx?lsr=0756&sy=2025&sortoption=&txtsessionyear=2025&txtbillnumber=HB732